Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05427240 · ClinicalTrials.gov registry record · NA
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
A NA study of Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT05427240: Recruiting NA study of Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05427240 is a NA study of Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,000 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05427240, a NA study of Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.
Primary Outcome
Change in Knowledge - Score Range = 0-16, Higher score = Better outcome
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER Pre-Test Intervention
- OTHER Post-Test Intervention
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
What NCT05427240 shows while recruiting
NCT05427240 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT05427240 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05427240 about?
NCT05427240 is a clinical study titled "eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer". This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optima...
What is the current status of trial NCT05427240?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2022-09-28. Estimated completion is 2026-07-01.
What conditions does trial NCT05427240 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT05427240?
The interventions under investigation include: Standard of Care (OTHER), Pre-Test Intervention (OTHER), Post-Test Intervention (OTHER).
Who is sponsoring clinical trial NCT05427240?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05427240 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05427240's enrollment target sits among peer trials
1,000 80th of 615 higher than 531 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI